Whether biopharmaceutical companies have one candidate or 100, the directive is clear: moving quickly into FIH testing is essential. But, how?
Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies.
For small biopharma innovators, steep development costs are compounded by the fact that large molecules are becoming increasingly complex and present serious clinical or manufacturing problems.
It’s no secret that drug forecasts are notoriously incorrect, and often by large margins. With no signs of improvement in forecasting accuracy, how do companies minimize risk?
While forecasts can never be 100 percent accurate, the goal for biopharmaceutical forecasters should be to minimize the degree of inaccuracies as much as possible.
From discussions with pharmaceutical and biotechnology industry leaders, it is clear that demand forecasting is a significant challenge when planning biologic drug substance production.
Inaccurate demand forecasts can have significant implications for companies developing biologics. And, it is increasingly difficult to locate capacity to respond to demand changes.
Thermo Fisher Scientific
4721 Emperor Blvd., Suite 200
Durham, NC 27703-8580
Phone: +1 919 226 3200